A 26 Week Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of Various Doses of HPP404 on Weight Loss in Overweight or Obese Subjects.
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2014
At a glance
- Drugs HPP 404 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors High Point Pharmaceuticals
- 14 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2012 Planned End Date changed from 1 Feb 2013 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 29 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.